Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to assess the efficacy of everolimus in patients with metastatic renal cell cancer whose disease progressed on or after prior first-line treatment with sunitinib or pazopanib. Efficacy will be measured by the rate of patients who are free of disease progression after 6 months of treatment with everolimus.
Critère d'inclusion
- Metastatic Renal Cell Carcinoma